Literature DB >> 1415942

Long-term follow-up of partial splenectomy in Gaucher's disease.

I J Cohen1, K Katz, E Freud, M Zer, R Zaizov.   

Abstract

Seven children with Gaucher's disease who underwent partial splenectomy were followed for 7 to 8 years. None of the children had systemic sepsis or symptoms related to liver enlargement. Bone crisis occurred in only two children who had experienced bone crisis prior to partial splenectomy. This contrasts with the development of bone crises in five of six children who underwent total splenectomy at a similar age and who had previously been free of bone symptoms. Partial splenectomy should be regarded as a temporary solution in the treatment of hypersplenism and the mechanical compression related to the huge spleen. In 71% of the patients, massive enlargement and a severe to moderate degree of pancytopenia occurred again after 3 to 8 years; total splenectomy was required in three patients.

Entities:  

Mesh:

Year:  1992        PMID: 1415942     DOI: 10.1016/s0002-9610(05)80902-x

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  4 in total

Review 1.  Current issues in enzyme therapy for Gaucher disease.

Authors:  G A Grabowski
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

2.  The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study.

Authors:  A M Damiano; G M Pastores; J E Ware
Journal:  Qual Life Res       Date:  1998-07       Impact factor: 4.147

Review 3.  Hereditary spherocytosis and partial splenectomy in children: review of surgical technique and the role of imaging.

Authors:  Caroline L Hollingsworth; Henry E Rice
Journal:  Pediatr Radiol       Date:  2010-02-24

4.  Effective treatment of painful bone crises in type I gaucher's disease with high dose prednisolone.

Authors:  I J Cohen; L Kornreich; S Mekhmandarov; K Katz; R Zaizov
Journal:  Arch Dis Child       Date:  1996-09       Impact factor: 3.791

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.